Cargando…

Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm

Background: Patients with advanced or recurrent endometrial cancer (EC) have limited treatment options following platinum-based chemotherapy and poor prognosis. The single-arm, Phase I GARNET trial (NCT02715284) previously reported dostarlimab efficacy in mismatch repair–deficient/microsatellite ins...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goulden, Scott, Shen, Qin, Coleman, Robert L., Mathews, Cara, Hunger, Matthias, Pahwa, Ankit, Schade, Rene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Columbia Data Analytics, LLC 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493167/ https://www.ncbi.nlm.nih.gov/pubmed/37701519 http://dx.doi.org/10.36469/001c.77484

Ejemplares similares

Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England
por: Goulden, Scott, et al.
Publicado: (2023)

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
por: Oaknin, Ana, et al.
Publicado: (2023)

Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
por: Kristeleit, Rebecca, et al.
Publicado: (2022)

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
por: Mathews, Cara, et al.
Publicado: (2022)

An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer
por: Bartoletti, Michele, et al.
Publicado: (2022)

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
por: Oaknin, Ana, et al.
Publicado: (2022)

Dostarlimab: A Review
por: Costa, Bárbara, et al.
Publicado: (2022)

An Integrated Analysis of Dostarlimab Immunogenicity
por: Lu, Sharon, et al.
Publicado: (2021)

Correction to: An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
Publicado: (2022)

Dostarlimab: A breakthrough in the field of oncology
por: Hussain, Hassan ul, et al.
Publicado: (2022)

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
por: You, Maojin, et al.
Publicado: (2023)

Dostarlimab/tozinameran: Various toxicities: case report
Publicado: (2022)

Dostarlimab: The miracle drug for the treatment of colorectal cancer
por: Shuvo, Pollob Ahmed, et al.
Publicado: (2022)

Jemperli (Dostarlimab-gxly): An unprecedented cancer trial
por: Ali, Eman, et al.
Publicado: (2022)

(18)F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab
por: Seban, Romain-David, et al.
Publicado: (2021)

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial
por: Oaknin, Ana, et al.
Publicado: (2020)

Dostarlimab: From preclinical investigation to drug approval and future directions
por: Cicala, Carlo Maria, et al.
Publicado: (2023)

Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma
por: Madariaga, Ainhoa, et al.
Publicado: (2023)

Selection rules for all-optical magnetic recording in iron garnet
por: Stupakiewicz, A., et al.
Publicado: (2019)

Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
por: Singh, Vanshikha, et al.
Publicado: (2022)

Dostarlimab, a boon or a healthcare burden- too early to acertain!
por: Fatima, Nabeela, et al.
Publicado: (2022)

Immune checkpoint inhibitor-induced encephalitis with dostarlimab in two patients: Case series
por: Marzoughi, Sina, et al.
Publicado: (2021)

Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer
por: Alkholifi, Faisal K., et al.
Publicado: (2022)

Jet classiﬁcation with GarNet
por: Leite, Julia Carvalho
Publicado: (2021)

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
por: André, Thierry, et al.
Publicado: (2023)

The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?
por: Coleman, Robert L.
Publicado: (2020)

Population pharmacokinetics and exposure–response of anti‐programmed cell death protein‐1 monoclonal antibody dostarlimab in advanced solid tumours
por: Melhem, Murad, et al.
Publicado: (2022)

The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy
por: Jeong, Tae-Jun, et al.
Publicado: (2022)

Solid electrolytes for advanced applications: garnets and competitors
por: Murugan, Ramaswamy, et al.
Publicado: (2020)

Garnet, the archetypal cubic mineral, grows tetragonal
por: Cesare, B., et al.
Publicado: (2019)

Laser Synthesis of Cerium-Doped Garnet Nanoparticles
por: Vasylkovskyi, Volodymyr, et al.
Publicado: (2023)

External rotation during elevation of the arm
por: Inui, Hiroaki, et al.
Publicado: (2009)

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
por: Yap, Timothy A, et al.
Publicado: (2022)

Building External Control Arms From Patient-Level Electronic Health Record Data to Replicate the Randomized IMblaze370 Control Arm in Metastatic Colorectal Cancer
por: Schröder, Carsten, et al.
Publicado: (2021)

Creation of an ustekinumab external control arm for Crohn’s disease using electronic health records data: A pilot study
por: Rudrapatna, Vivek A., et al.
Publicado: (2023)

Garnet Crystal Growth in Non-precious Metal Crucibles
por: Sidletskiy, O, et al.
Publicado: (2019)

GARNET – gene set analysis with exploration of annotation relations
por: Rho, Kyoohyoung, et al.
Publicado: (2011)

Effect of Storage on the Nutritional Quality of Queen Garnet Plum
por: Kodagoda, Gethmini, et al.
Publicado: (2021)

Stabilization of garnet/Li interphase by diluting the electronic conductor
por: Feng, Wuliang, et al.
Publicado: (2022)

Standardizing critical current density measurements in lithium garnets
por: Klimpel, Matthias, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uh3sm3ap5d4gomlsan7vhe8bdr